Integration of Novel Diagnostics into Clinical Practice

Similar to drug and device markets, a critical part of the success of novel diagnostics is educating providers on clinical and therapeutic utility.  However, unlike pharmaceutical drugs, the ordering of a diagnostic test does not necessarily imply a change in… Continue Reading

Removing Bias from HEOR: Standardizing the Costs of Adverse Events

What are the total costs of prescribing a particular drug? At its core, all health economics and outcomes research (HEOR) studies are designed to answer this fundamental question. And it is this answer that helps to remove barriers to market… Continue Reading

21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety

As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. In my view, no organization should have monopolistic control over important information that limits the ability for healthcare decision makers to perform unbiased, objective comparative… Continue Reading

Optimized Value Analytics – The Next Frontier for Payers and Pharma?

By Caitlin Rothermel, MA, MPHc Introduction If you’ve been following the health economics industry for the past few years, you’ve heard about value-based pricing agreements between payers and the pharmaceutical industry. With value-based approaches, payment is linked directly to real-world treatment… Continue Reading